Lupin, Exeltis ink agreement for Bacterial Vaginosis, Trichomoniasis drug SOLOSEC
Solosec is a single-dose therapy for oral use.
Mumbai: Lupin Pharmaceuticals Inc. and Exeltis USA Inc. have recently announced a promotional agreement for Exeltis to promote SOLOSEC along with Exeltis' existing line of Women's Health products, further enhancing value to OBGYNs and their patients.
SOLOSEC is indicated for the treatment of Bacterial Vaginosis in adult women (a common vaginal infection) and Trichomoniasis in adults (the most common non-viral, curable sexually transmitted infection in the U.S.).
SOLOSEC is a single-dose therapy for oral use. The entire contents of SOLOSEC packet should be sprinkled onto applesauce, yogurt or pudding and consumed once within 30 minutes without chewing or crunching the granules. SOLOSEC is not intended to be dissolved in any liquid. Avoid consumption of alcoholic beverages and preparations containing ethanol or propylene glycol during treatment with SOLOSEC and for at least 2 days after completing therapy.
"This partnership will expand the reach of SOLOSEC, allowing more Healthcare Providers to be aware of the benefits of SOLOSEC, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis," said Vinita Gupta, Chief Executive Officer of Lupin "We are extremely excited to partner with Exeltis."
Salustiano Perez, Chief Executive Officer of Exeltis added, "Our team is thrilled to embark on this partnership. The addition of Solosec fits precisely within our current portfolio of products, enhancing our commercial strategy, and offering numerous solutions to our customers and their patients".
SOLOSEC is a registered trademark owned by Lupin Inc.
Lupin is an Innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APls in over 100 markets In the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle East regions
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.